UBS analyst Eliana Merle raised the firm’s price target on Apellis to $64 from $60 and keeps a Buy rating on the shares. The company’s update on injections kits and the vasculitis case reports was overall a positive, including number of vials shipped in Q3-to-date, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on APLS:
- Apellis (NASDAQ:APLS) Soars After Giving Safety Update on Drug
- Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)
- Apellis provides update on supplied injection kits
- Apellis Pharmaceuticals call volume above normal and directionally bullish
- Stifel believes GA market is large enough for Apellis’ Syfovre